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Abstract
Background: The R192Q mutation of the CACNA1A gene, encoding for the a1 subunit of voltage-gated P/Q Ca
2+
channels (Cav2.1), is associated with familial hemiplegic migraine-1. We investigated whether this gain-of-function
mutation changed the structure and function of trigeminal neuron P2X3 receptors that are thought to be
important contributors to migraine pain.
Results: Using in vitro trigeminal sensory neurons of a mouse genetic model knockin for the CACNA1A R192Q
mutation, we performed patch clamp recording and intracellular Ca
2+ imaging that showed how these knockin
ganglion neurons generated P2X3 receptor-mediated responses significantly larger than wt neurons. These
enhanced effects were reversed by the Cav2.1 blocker ω-agatoxin. We, thus, explored intracellular signalling
dependent on kinases and phosphatases to understand the molecular regulation of P2X3 receptors of knockin
neurons. In such cells we observed strong activation of CaMKII reversed by ω-agatoxin treatment. The CaMKII
inhibitor KN-93 blocked CaMKII phosphorylation and the hyperesponsive P2X3 phenotype. Although no significant
difference in membrane expression of knockin receptors was found, serine phosphorylation of knockin P2X3
receptors was constitutively decreased and restored by KN-93. No change in threonine or tyrosine phosphorylation
was detected. Finally, pharmacological inhibitors of the phosphatase calcineurin normalized the enhanced P2X3
receptor responses of knockin neurons and increased their serine phosphorylation.
Conclusions: The present results suggest that the CACNA1A mutation conferred a novel molecular phenotype to
P2X3 receptors of trigeminal ganglion neurons via CaMKII-dependent activation of calcineurin that selectively
impaired the serine phosphorylation state of such receptors, thus potentiating their effects in transducing
trigeminal nociception.
Background
Migraine is a common debilitating neurovascular disor-
der with complex etiology that is clinically divided into
two main subtypes based on the absence or presence of
an aura that is characterized by transient visual, sensory
and/or speech related neurological symptoms [1]. Most
molecular genetic insight in the pathophysiology of
migraine comes from studies of a rare monogenic sub-
type of migraine with aura, called Familial Hemiplegic
Migraine type 1 (FHM-1) [2]. FHM-1 is due to muta-
tions in the a1 subunit of voltage-gated CaV2.1 (P/Q-
type) Ca
2+ channels [3]. Transgenic knock-in (KI) mice
carrying a FHM-1 glutamine for arginine (R192Q) muta-
tion revealed increased glutamate release in the cortex
that explains their increased susceptibility to cortical
spreading depression (CSD) [4,5], the electrophysiologi-
cal correlate of the human migraine aura [6]. Patch
clamp analysis of transfected neurons expressing human
R192Q-mutant a1 protein revealed facilitated activation
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2+ influx as the
underlying molecular mechanism [7]. Whereas there is
little doubt that CSD causes the aura, the mechanisms
leading migraine headache are less clear. The current
view is that the headache is caused by the trigeminovas-
cular system that releases a number of “migraine media-
tors” activating nociceptive receptors expressed by
trigeminal neurons [8]. Previous studies from our group
have indicated that migraine mediators (e.g., nerve
growth factor and calcitonin gene-related peptide) can
persistently sensitize trigeminal sensory neurons [9-11]
and that enhanced pain perception involves activation of
neuronal P2X3 receptors by extracellular ATP [12]. The
role of trigeminal sensory neuron P2X3 receptors as
important contributors to migraine pain has recently
been discussed [13-16].
T h ep r e s e n ts t u d yu s e dR 1 9 2 QK Im i c et oi n v e s t i g a t e
peripheral pain mechanisms at the level of trigeminal
sensory neurons to explore whether they show evidence
of enhanced pain transduction. Since CaV2.1 Ca
2+ chan-
nels normally are expressed by trigeminal sensory neu-
rons and contribute by approximately 40% to voltage-
gated Ca
2+ influx [17], we assessed whether the R192Q
mutation might introduce a cascade of Ca
2+-dependent
signals controlling expression and function of the main
pain receptors P2X3 and TRPV1 [18-21]. Although we
observed unchanged activity of TRPV1 receptors in
mutant mouse sensory neurons, we detected a signifi-
cant increase in P2X3 receptor activity that was charac-
terized by combining electrophysiological and molecular
biology techniques.
Results
CaV2.1 R192Q KI trigeminal neurons show enhanced
membrane currents mediated by P2X3 receptors
Because the large majority oft r i g e m i n a lg a n g l i o nn e u -
rons typically express P2X3 receptors [22] that are impli-
cated in pain transducing mechanisms in migraine [8],
we investigated whether the CaV2.1 channel a1 subunit
R192Q mutation affected P2X3 receptor function. Fig.
1 As h o w se x a m p l e so fc u r r e n tt r a c e si n d u c e db ya2 - s
application of the selective P2X3 receptor agonist a,b-
meATP (10 μM) to WT and R192Q KI neurons. On
WT neurons, the fast-developing inward current was on
average -354 ± 28 pA (n = 154) and then fully desensi-
tized during agonist application, a characteristic typical
of currents mediated by P2X3 receptors [18]. On R192Q
KI neurons, the peak amplitude of a,b-meATP-evoked
current was, on average, -547 ± 32 pA (n = 183: p =
0.035 from WT) with subsequent full desensitization.
Fig. 1B shows average concentration-response plots for
WT (n = 18) and R192Q KI (n =1 7 )n e u r o n st e s t e d
with a,b-meATP. The R192Q KI plot revealed a signifi-
cantly larger maximal response compared to WT
without changing the a,b-meATP potency (EC50 = 6.9 ±
1.1 μM for WT; 4.3 ± 0.8 μM for KI) or the Hill coeffi-
cient (0.86 ± 0.34 for WT; 1.11 ± 0.34 for KI). Other
parameters of P2X3 receptor function, such as current
rise-time (τon), desensitization onset (τfast), and recovery
from desensitization at 30 s interpulse interval, were not
significantly different between genotypes (Fig. 1C).
Mouse trigeminal neurons usually express a low level of
heteromeric P2X2/3 receptors mediating a sustained
inward current following the initial transient peak [22].
In the present study no significant difference in the
amplitude or occurrence of heteromeric responses (mea-
sured at steady state) was observed between WT and KI
neurons (-60 ± 6 pA in WT, n = 53; 34% incidence and
-61 ± 8 pA in KI, n = 47; 25% incidence).
Fig. 1D,E shows the amplitude distribution of current
responses evoked by a,b-meATP (10 μM) in WT and
R192Q KI neurons (n =4 5 4a n dn = 414, respectively).
Because of the heterogeneity of trigeminal sensory neu-
rons in culture, responses were further analyzed in
terms of cell capacitance, which reflects the cell size. In
view of the distribution of P2X3 receptor expression
[22], we restricted our sampling to neurons that are lar-
ger than 15 μmi nd i a m e t e r .F i g .1 Es h o w st h a t
enhanced responses to a,b-meATP were observed in a
population of neurons with 15-35 pA/pF current density
value that matched the somatic size profile shown in
Fig. 1D. This upregulation of P2X3 receptor function
was not due to increased receptor synthesis and/or
expression at membrane level as indicated by real time
RT-PCR data (Fig. 2A) and membrane biotinylation
results (Fig. 2B; p > 0.05) performed in accordance with
our previous studies [9,10]. Current responses induced
by 1 μM capsaicin, a selective agonist of TRPV1 chan-
nels, were not significantly different between WT (-38 ±
3p A ;n =6 4 )a n dK I( - 4 0±4p A ;n =8 0 )n e u r o n sa s
exemplified by the middle panel of Fig. 2C. mRNA
synthesis and immunohistochemical expression of
TRPV1 and P2X2 receptors was similar between WT
and KI (Fig. 2C,D).
The enhanced responses of P2X3 receptors on KI neu-
rons were probably related to the CaV2.1 R192Q chan-
nel activity because pre-treatment of KI cultures with
the selective inhibitor ω-agatoxin (200 nM; 30 min) pro-
duced KI neuronal responses to a,b-meATP that were
52 ± 4.5% (n = 17) of untreated KI (n = 19; p = 0.001).
Pretreatment of WT neurons with ω-agatoxin induced
only a relatively minor decrease in amplitude of P2X3
currents (71 ± 3.5%; n = 10 vs. untreated WT cells
taken as 100%; n = 14).
Intracellular Ca
2+ transients of CaV2.1 R192Q neurons
Without perturbing intracellular Ca
2+ homeostasis with
the whole-cell patch clamp method, we tested the
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Page 2 of 17Figure 1 Functional characterization and expression of P2X3 receptors in WT and R192Q KI trigeminal ganglion neurons. A,
Representative current traces induced by a,b-meATP (10 μM, 2-s application) on WT and KI neurons. B, Dose-response curves for WT (n = 18,
filled circles) and KI (n = 17, open circles) cells. * p = 0.04, ** p = 0.035, ***p = 0.03. Note larger responses of a,b-meATP-mediated currents on KI
neurons with respect to WT, as the dose-effect plot is shifted upwards for KI neurons. C, Rise time (left; expressed as τon calculated on the 10-
90% response rise), desensitization onset (middle; expressed as the first time constant, τfast, of current decay) and recovery from desensitization
(right; expressed as% of control amplitude in a paired pulse agonist application) of P2X3 receptor currents are similar for WT and KI neurons. All
responses were evoked by a,b-meATP (10 μM, 2 s). n = 154 for WT and n = 183 for KI. D, Histograms show peak amplitude distribution of a,b-
meATP (10 μM)-induced P2X3 currents for WT (n = 414, open bars) and KI (n = 454, filled bars). E, Histograms show the distribution of current
density (i.e., current amplitude normalized with respect to the neuronal capacitance, pA/pF) for WT (n = 414, open bars) and KI (n = 454, filled
bars) neurons, indicating significantly higher a,b-meATP-evoked KI responses over a span of 15-35 pA/pF values compared to WT.
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Page 3 of 17contribution of P/Q-type channels to intracellular Ca
2+
levels following depolarizing pulses of K
+ or a,b-
meATP. This approach enabled us to test the
excitability (in terms of intracellular Ca
2+ transients) of
trigeminal sensory neurons [10]. To this end, we com-
pared Ca
2+ transients evoked by these stimuli before
and after 30 min application of ω-agatoxin (200 nM) to
WT or KI neurons. It is noteworthy that the size of the
intracellular Ca
2+ rise induced by a,b-meATP was sig-
nificantly smaller than the one elicited by K
+ presum-
ably because the amplitude of neuronal membrane
depolarization (and its duration) evoked by K
+ was
Figure 2 Expression of pain receptors in WT and KI neurons. A, Real-time RT-PCR experiments of mRNA extracts from trigeminal ganglia
show no significant difference in P2X3 mRNA expression levels between WT and KI mice (n =3 ,p > 0.05). Data were normalized with respect to
b-tubulin III housekeeping mRNA content. B, Biotinylation experiments of trigeminal neurons in culture show no significant differences in P2X3
membrane protein expression levels between WT and KI mice (n =4 ,p > 0.05). C, Real time RT-PCR experiments to measure mRNA expression
levels of TRPV1 (left) and P2X2 (right) receptor subunits show no significant difference between trigeminal ganglia from WT and KI mice. n =3p
> 0.05. Middle panel shows examples of TRPV1 receptor mediated responses evoked by capsaicin (1 μM) from WT or KI neuron, indicating
similar amplitude and duration. D, Microphotographs show immunoreactivity of TRPV1 and P2X2 proteins in cultured trigeminal neurons from
WT or KI mice. Histograms (right) represent% of immunoreactive neurons for TRPV1 (top) and P2X2 (bottom) over b-tubulin III immunoreactive
neurons. n =5 ,p > 0.05.
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Page 4 of 17much larger and, thus activated a wider population of
Ca
2+ channels [10,22]. This finding is corroborated by
the data shown in Fig. 3A.
D e s p i t ec o m p a r a b l el e v e l so f dye loading and similar
responses to rather high (50 mM) pulse application of
K
+ (not shown), we consistently found that KI neurons
produced significantly (p=0.005) larger Ca
2+ transients
(Fig. 3B) when stimulated with a lower concentration
(20 mM) of K
+. We also observed that 78% of KI neu-
rons (n = 35/45) were sensitive to ω-agatoxin inhibition
(i.e., showed a response decrease of >10%), whereas in
the case of WT neurons, only 50% (n = 14/28) were
sensitive to this toxin. Fig. 3B indicates that, following
application of ω-agatoxin, the depression of Ca
2+ transi-
ents induced K
+ was proportionally similar in WT and
KI neurons (27 ± 4%, n = 14; and 30 ± 3%, n =3 5 ,
respectively), indicating that the toxin-sensitive contri-
bution to the global Ca
2+ transient was not affected by
the CaV2.1 mutation that is reported to affect only the
activation threshold of P/Q-type channels [4,5].
In line with these results, we also observed that Ca
2+
transients induced by a,b-meATP (10 μM) on KI neu-
rons were larger (p = 0.04) than on WT neurons (Fig.
3C,D), although a similar percentage of WT (47%) and
KI (46%) neurons were sensitive to a,b-meATP. On the
same neurons tested before and after 30 min application
of ω-agatoxin (200 nM), a,b-meATP-evoked Ca
2+
responses were inhibited in 56% WT and 85% KI neu-
rons. Fig. 3D demonstrates that, on average, ω-agatoxin
significantly (p <0 . 0 0 1 )d e p r e s s e ds u c hC a
2+ transients
of KI or WT neurons with respect to untreated cells.
Furthermore, the decrease in Ca
2+ transient amplitude
by ω-agatoxin was significantly (p =0 . 0 4 )l a r g e r( 4 3±
2%, n = 22) for KI neurons than for WT neurons (30 ±
2%, n = 9). Nevertheless, after ω-agatoxin, the residual
Ca
2+ response to a,b-meATP was similar for WT and
KI neurons (see Fig. 3D) probably because the size of
the depolarization elicited by a,b-meATP was not large
enough to activate a major fraction of the high thresh-
old Ca
2+ channels [22]. Thus, this residual response was
likely made up by the analogous Ca
2+ permeability
through P2X3 receptor channels of WT and KI neurons.
Immunohistochemical analysis of trigeminal ganglion
cultures showed that the number of immunopositive
neurons for CaV2.1 channels and P2X3 receptors was
similar between genotypes (Fig. 3E). We also investi-
gated (by double immunofluorescence with anti-P2X3
and anti-CaV2.1 antibodies) the fraction of CaV2.1
immunoreactive neurons expressing P2X3 receptors as
well: this number amounted to 68 ± 4% for WT and 66
±3 %f o rK I( n =7 ,p > 0.05) for small-medium neurons
(<20 μm), suggesting a large, though not complete,
occurrence of protein co-expression. In fact, when we
examined the number of P2X3 immunoreactive neurons
that were positive for CaV2.1, we found 42 ± 3% and
43 ± 4% for WT and KI, respectively (n =4 ) .T h e s e
observations were consistent with a functional interac-
tion between these proteins in a subpopulation of sen-
sory neurons.
High CaMKII activity confers enhanced P2X3 receptor
phenotype to KI trigeminal neurons
To discover the mechanisms responsible for the
enhanced activity of trigeminal P2X3 receptors despite
no change in their expression levels, we studied whether
the molecular regulation of the receptors was changed
by the R192Q gain-of-function mutation of CaV2.1
channels. Our previous studies have demonstrated that
changes in P2X3 receptor activity could be brought
about by pharmacological manipulations affecting the
phosphorylation state of the receptor, rather than its
expression level [9,23,12]. Thus, it seemed likely that the
origin of the augmented P2X3 receptor activity of KI
neurons might reside in a changed phosphorylation
state of the intracellular protein domains. It is likely that
increased Ca
2+ influx via mutated CaV2.1 channels may
regulate multiple intracellular Ca
2+-dependent signalling
mechanisms via altering the physiological function of
many Ca
2+ binding proteins, amongst which CaMKII is
a likely contributor [24,25]. For these reasons, immuno-
fluorescence experiments were performed with antibo-
dies selective for active CaMKII phosphorylated at
Thr286 [11] that showed a larger number of immunopo-
sitive trigeminal neurons in culture (45 ± 5%), and intact
ganglia (36 ± 6%) from KI mice (Fig. 4A). By compari-
son, CaMKII immunoreactivity was detected only in
15 ± 4 and 9 ± 3% of neurons in cultures or intact
ganglia from WT mice (n =3 - 5 ;p = 0.03; see example
in Fig. 5A). Previous experiments have confirmed the
antibody selectivity by showing that its signal was
blocked by the CaMK inhibitor KN-93 in immunofluor-
ence and western blotting [11].
Immunoblotting performed on protein extracts from
trigeminal ganglia and cultures further demonstrated
that, despite the lack of change in total CaMKII level
between WT and KI (n =4 ,p > 0.05; Fig. 4B), the active
fraction of CaMKII (T286-phosphorylated) was signifi-
cantly larger in KI than WT (Fig. 4B; n =4 ,p =0 . 0 3 ) .
We also observed that the larger activation of CaMKII
in KI samples was due to the presence of mutated
CaV2.1 channel activity, because pretreatment with ω-
agatoxin (200 nM, 24 h) significantly (p = 0.027; n =4 )
reduced the CaMKII signal (Fig. 4B). Increased CaMKII
activity in KI neurons was not apparently accompanied
by an overactivation of the CREB transcription factor
compared with that in WT neurons (Fig. 4C, see [11]).
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Page 5 of 17Figure 3 Ca
2+ transients evoked by K
+ depolarization or P2X3 receptors in WT and R192Q KI neurons. A, Examples of Ca
2+ transients of
trigeminal neurons evoked by KCl (20 mM, 2-s application) before (black trace) and after (red trace) application of ω-agatoxin (200 nM, 30 min).
B, KI neurons show significant increase in KCl (20 mM, 2-s application) mediated Ca
2+ transients compared to WT (*p = 0.005, n = 28 and n = 45,
in WT and KI, respectively). Histograms also represent inhibition by ω-agatoxin of Ca
2+ transients for WT (n = 14) and KI (n = 35) neurons. After
ω-agatoxin responses of WT and KI neurons differ from their own controls (**p ≤ 0.001). C, Representative traces of a,b-meATP (10 μM, 2-s
application)-evoked Ca
2+ transients before (black trace) and after (red trace) application of ω-agatoxin (200 nM, 30 min). D, Histograms show
larger Ca
2+ transients evoked by a,b-meATP (10 μM, 2-s application) from KI (n = 26) than WT (n = 16) and neurons (*p = 0.04). Histograms also
show that ω-agatoxin reduced Ca
2+ transients of KI (n = 22) and WT (n = 9) neurons. **p ≤ 0.001 for each case. E, Microphotographs of
immunofluorescence experiments depicting WT and KI trigeminal neurons in culture expressing P2X3 receptors or CaV2.1 channels. Bar =5 0μm.
Histograms (right) show% of P2X3- (top) or CaV2.1- (bottom) immunoreactive neurons (taking as 100% the b-tubulin III immunoreactive) (n =5 ,p
> 0.05 for P2X3 receptors; n =3 ,p > 0.05 for CaV2.1-expressing neurons). F, Histograms show% of CaV2.1-immunoreactive neurons (top; taken as
100%) which are immunopositive for P2X3 (n =7 ,p > 0.05) or% of P2X3-immunoreactive neurons (bottom) which are immunopositive for CaV2.1
(n =4 ,p > 0.05).
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Page 6 of 17R192Q KI neurons lack constitutive serine
phosphorylation of P2X3 receptors
The observation of strong CaMKII activation in KI neu-
rons led us to examine the phosphorylation state of
their P2X3 receptors. Hence, we screened immunopreci-
pitated P2X3 receptors from WT and KI trigeminal neu-
rons with antibodies against phosphorylated residues.
Fig. 5A,B shows that P2X3 receptor serine-phosphoryla-
tion was significantly reduced in extracts of trigeminal
cultures (n =5 ,p = 0.02) from KI compared with WT.
Although significant, this difference was not very large
probably because the number of P2X3 receptor expres-
sing neurons that also expressed CaV2.1 channels was
less than 50% of the total population whose contribution
diluted the overall change (see Fig. 3F). Notwithstanding
this issue, the dissimilar level of P2X3 receptor serine-
phosphorylation was also found between KI and WT
ganglia (n =3 ,p = 0.04; data not shown). It is note-
worthy that the antibodies we used for studying the
phosphorylated aminoacid residues were not sequence-
specific and, therefore, did not allow us to identify the
consensus sequence of the receptor domain responsible
for conferring the upregulated phenotype of KI neurons.
When cultures were preincubated with ω-agatoxin
(200 nM, 24 h), P2X3 serine phosphorylation was signifi-
cantly (p = 0.027) increased in KI neurons (n =3 ;
Figure 4 CaMKII activation of R192Q KI trigeminal neurons is reversed by ω-agatoxin. A, Microphotographs of immunofluorescence
experiments with anti-phospho Thr286 CaMKII antibody (recognizing the active form of CaMKII) of WT and KI trigeminal ganglia (left panel)o r
trigeminal neurons in culture (right panel). Bar =5 0μm. B, Example of western immunoblots of total protein lysate from WT and KI trigeminal
neurons in culture using antibodies recognizing the active form of CaMKII (phosphorylated Thr286, upper lanes) or anti-total CaMKII antibody
(middle lanes). Equal loading was tested with b-tubulinIII antibodies (bottom lanes). p = 0.03, (n = 4). CaMKII activation is prevented by treatment
with ω-agatoxin (200 nM, 24 h). Histograms (right) demonstrate significant increase in active (threonine-phosphorylated) CaMKII in KI neurons, an
effect prevented by ω-agatoxin (n =4 ,# p = 0.027). C, Western immunoblot experiments of trigeminal ganglia from WT and KI mice, using the
same anti-phospho-CREB antibody (43 kDa). Gel loading quantification is obtained using anti-b-tubulinIII antibody. Histograms (right) show no
significant difference in CREB phosphorylation between the two conditions. n =3 ,p > 0.05.
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Page 7 of 17Figure 5 Phosphorylation state of P2X3 receptors in KI neurons. A, Example of western blots of P2X3 receptors immunopurified from WT
and KI neurons and probed with anti-phosphorylated serine antibodies. Note decreased serine phosphorylation of KI samples, a phenomenon
prevented by pre-treatment with ω-agatoxin (200 nM, 24 h). B, Histograms quantify serine phosphorylation state of P2X3 receptors (*p = 0.02 vs.
WT; n = 5) that is enhanced for KI receptors and prevented by ω-agatoxin (n =3 ,# p = 0.027). C, Example of western blots of immunopurified
P2X3 receptors from WT and KI neurons probed with anti-phosphorylated threonine (top row) or tyrosine (middle row) antibodies. Total P2X3
receptor levels are shown in bottom row. Control antibody lane (Ab) is also shown. n = 8 for threonine and n = 3 for tyrosine. D, Pretreatment
of neurons with the CaMKII inhibitor KN-93 (5 μM, 90 min) restores the P2X3 serine phosphorylation state without changing total P2X3 receptor
expression. Histograms (right) quantify serine phosphorylation state of P2X3 receptors, an effect blocked by KN-93 (n =3 ;* p = 0.02; #p = 0.017)
in KI neurons. E, Representative examples of WT and KI current traces evoked by a,b-meATP (10 μM, 2-s application) in control (Ctr) and after
pre-treatment with KN-93 (5 μM, 90 min). Histograms (right) show the percent inhibition by KN-93 of peak amplitude of a,b-meATP-mediated
P2X3 receptor currents in KI neurons (n = 22), that is significantly larger in KI cells (n = 17, *p = 0.039).
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Page 8 of 17Fig. 5A). We observed no significant change in threo-
nine (n = 5) or tyrosine phosphorylation level (n =5 ,
p > 0.05; Fig 5C). These results suggest that R192Q
mutation in CaV2.1 channels conferred to KI trigeminal
neurons a molecular phenotype with constitutively
depressed serine phosphorylation of P2X3 receptors,
together with upregulation of P2X3 receptor-mediated
currents.
The change in P2X3 receptor serine phosphorylation
of KI neurons was linked to high CaMKII activity
because pre-application of the selective CaMKII inhibi-
tor KN-93 (5 μM; 90 min; Fig. 5D) to KI cultures
reversed this phenotype and restored a level of serine
phosphorylation analogous to the WT one. Conversely,
KN-93 had no effect on WT serine P2X3 phosphoryla-
tion probably because of the constitutively low level of
CaMKII activity in these cells (see Fig. 4A,B). Patch-
clamp data validated our findings because, whereas KN-
9 3d i dn o ts i g n i f i c a n t l yc h a n g em e m b r a n ec u r r e n t s
evoked by a,b-meATP (10 μM) from WT neurons (n =
17), it significantly (p = 0.039) attenuated currents
recorded from KI neurons (n = 22; Fig. 5E).
These data suggest that CaV2.1 channel-mediated acti-
vation of CaMKII exerted a positive effect on P2X3
receptor current of KI neurons by inhibiting serine
phosphorylation.
Serine dephosphorylated P2X3 receptors of KI neurons
show increased function
We have recently observed P2X3 receptor serine phos-
phorylation by Cdk5 to be a powerful negative regulator
of receptor function [26]. In keeping with the enhanced
functional responses of KI neurons, we compared the
expression of Cdk5 in WT and KI neurons. The percent
of trigeminal neurons expressing Cdk5 was similar in
WT and KI (61 ± 2%) cultured neurons (n =3 ,p >
0.05). Western blotting of membrane fractions indicated
a significant overall decrease of Cdk5 expression in
lysates from KI ganglia (0.7 ± 0.025 fold change versus
WT; n =4 ,p = 0.04; Fig. 6A) together with lower P2X3/
Cdk5 co-immunoprecipitation (0.8 ± 0.02 fold change in
KI versus WT; n =3 ,p = 0.03; Fig. 6B) despite analo-
gous levels of total Cdk5 expression (see Fig. 6A), sug-
gesting a different compartmentalisation of this
molecules in KI neurons.
The observation of decreased P2X3 receptor serine
phosphorylation in KI neurons (see Fig. 5A) prompted
us to consider the potential role of phosphatases contri-
buting to this effect. The balance between phosphoryla-
tion and dephosphorylation is a primary means for
rapid regulation of a variety of neuronal functions, such
as membrane excitability, neurotransmitter release, and
receptor function [27]. Multiple families of serine/threo-
nine phosphatases have been identified in the brain,
including PP1, PP2A, PP2B, and PP2C families [28-30],
that are closely linked to intracellular Ca
2+. Calcineurin
(PP2B) is one major Ca
2+-dependent phosphatase that
controls the activity of membrane channels [31].
Although cell-free assays show that CaMKII can inhibit
calcineurin [32], in neuronal cell lines both CaMKII and
calcineurin are activated by Ca
2+ influx and are neces-
sary for Ca
2+-dependent signalling pathways [33].
Hence, we tested calcineurin involvement in P2X3
receptor phosphorylation state and function by incubat-
ing trigeminal neurons with the calcineurin inhibitor
FK-506 (5 μM, 30 min). This treatment reversed the KI
phenotype by decreasing the P2X3 receptor current (44
±5 % ,n =2 0 ,p = 0.03; Fig. 6C) and in KI increased
P2X3 receptor serine phosphorylation (134 ± 16%, n =
4, p = 0.03; Fig. 6D). To confirm the origin of this effect,
we applied the calcineurin inhibitor peptide (100 μM)
via the patch pipette during recording from WT or KI
neurons. In WT neurons recorded with the peptide
inhibitor filled pipettes there was a delayed (6-10 min)
rise in a,b-meATP peak currents (on average -427 ± 89
pA; n = 8 vs - 269 ± 35; n =2 0 ;p < 0.05), whereas for
KI neurons recorded with the same protocol there was
late decrease (-231 ± 28; n = 11 vs -477 ± 97, n =8 ;p <
0.01). These experiments suggest that calcineurin activ-
ity plays an important role in regulating P2X3 receptor
currents. Although calcineurin has been shown to facili-
tate desensitisation of P2X3 receptors expressed by
oocytes [34], on native P2X3 receptors of mouse gang-
lion neurons, application of the calcineurin inhibitor
FK-506 did not change the time constant of fast current
decay (τfast) in either WT or KI neurons (Table 1).
Application of FK-506 (5 μM, 30 min) to WT neurons
did not change constitutive P2X3 receptor serine phos-
phorylation levels (n =4 ,p =0 . 9 ;F i g .6 D ) ,s i g n i f i c a n t l y
increased WT receptor current amplitude (170 ± 13%, n
=1 8 ,p = 0.035; Fig. 6C) and enhanced P2X3 threonine
phosphorylation (Fig. 6E). The increase in WT receptor
current amplitude in the presence of the calcineurin
blocker was a phenomenon probably disjointed from
serine phosphorylation state and could perhaps be attri-
butable to increased P2X3 threonine phosphorylation
(146 ± 22%, n =5 ,p = 0.046) as previously reported for
WT neurons [9].
Discussion
The main finding of the present study is the novel
report of the phenotype of trigeminal ganglion neurons
from KI mice expressing a CaV2.1 a1 channel subunit
mutation that was previously found in FHM-1 patients
[3]. KI neurons showed enhanced P2X3 receptor activity
with decreased serine phosphorylation. This finding was
associated with an increased activation of CaMKII and
stronger a CaV2.1 (P/Q-type) mediated rise in
Nair et al. Molecular Pain 2010, 6:48
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Page 9 of 17Figure 6 Cdk5 and calcineurin modulate P2X3 receptors of trigeminal neurons. A, Example of western immunoblot using anti-Cdk5
antibodies on membrane extracts from WT and KI neurons. Total Cdk5 in the soluble fraction is also shown. Actin immunoblotting ensures
equal loading between WT and KI fractions (bottom row). Histograms (right) quantify average data (n =4 ,p = 0.04) of membrane Cdk5. B,
Example of co-immunoprecipitation experiments between P2X3 receptors and Cdk5 in WT and KI neurons showing decreased detection of Cdk5
in P2X3 immunopurified samples from KI neurons. Histograms (right) quantify lower Cdk5 signal from KI neurons (n =3 ,p = 0.03). C, Example of
current traces recorded from WT and KI trigeminal neurons evoked by a,b-meATP (10 μM, 2-s application) in control and after incubation with
FK-506 (5 μM, 30 min). Histograms (right) quantify the effect of FK-506 on the P2X3 receptor-mediated currents (n = 18, *p = 0.035 in WT
neurons and n = 20, *p = 0.027 in KI neurons). Data are normalized to the signals from WT neurons in control conditions. Note that FK-506
inhibits P2X3 current responses in KI neurons. D, Histograms of western blot signals obtained with anti-phosphorylated serine antibody applied
to immunopurified P2X3 receptors from WT and KI neurons in control condition and after incubation with FK-506 (5 μM, 30 min). Note increase
in serine phosphorylation after FK-506 treatment in KI neurons (n =5 ,* p = 0.02). Data are normalized to the signals from WT neurons in control
conditions. E, Histograms of western blot signals obtained with anti-phosphorylated threonine antibody show enhancement of threonine
phosphorylation in WT (n =5 ,* p = 0.046) as well as KI (n =3 ,* p = 0.04) in neurons after treatment with FK-506. Data are normalized to the
signals from WT neurons in control conditions.
Nair et al. Molecular Pain 2010, 6:48
http://www.molecularpain.com/content/6/1/48
Page 10 of 17intracellular Ca
2+. We envisage that such a phenotype
will facilitate trigeminal pain. To the best of our knowl-
edge, our results provide the first demonstration of
P2X3 receptor contribution to an animal model of a
neurological disease.
Functional characteristics of the R192Q KI mouse model
ATP-gated P2X3 and capsaicin-sensitive TRPV1 recep-
tors are representative of the two main classes of pain
transducers in trigeminal neurons [22]. We observed
potentiation of P2X3 receptor activity in trigeminal neu-
rons from KI mice without changes in potency or
desensitization of these receptors, and with no altered
occurrence (or size) of heteromeric P2X2/3 responses.
L i k e w i s e ,n oc h a n g ei nP 2 X 2 subunit expression was
detected. Responses to the TRPV1 receptor agonist cap-
saicin were also unaffected. Thus, our data indicate a
major gain of function of P2X3 receptors without their
concomitant overexpression at the plasma membrane or
al a r g e rn u m b e ro fP 2 X 3 receptor expressing neurons.
We set out to study whether such changes in P2X3
receptor function were indeed attributable to the gain of
function of R192Q-mutated CaV2.1 Ca
2+ channels in tri-
geminal neurons.
We showed that a subpopulation of P2X3 expressing
neurons also expressed CaV2.1 channels, thus providing
ample opportunity for their crosstalk. Indeed, intracellu-
lar Ca
2+ imaging showed that KI neurons had stronger
Ca
2+ transients evoked by a,b-meATP with a larger
component blocked by the CaV2.1 channel antagonist
ω-agatoxin, indicating that this effect was probably attri-
butable to overactivity of such mutated channels.
Furthermore, ω-agatoxin reversed the mutated pheno-
type of P2X3 receptors to WT, providing a functional
link between overactive CaV2.1 and P2X3 channels. It is,
however, noteworthy that in ganglia in situ or in culture
conditions, we observed no evidence for a deleterious
action by these enhanced channel activities as the num-
ber of neurons as well as the size distribution remained
similar to that in WT neurons.
Hence, the present data demonstrated a novel gain-of-
function produced by the R192Q mutation on P2X3
receptors of trigeminal ganglion neurons, that
complements the synaptic upregulation reported for
brain neurons [4,5].
Molecular mechanisms involved in enhanced P2X3
sensitivity of R192Q KI neurons
Interestingly, KI neurons from intact trigeminal ganglia
and in culture showed elevated basal activation of CaM-
KII (phosphorylation of its 286 threonine residue
[28,35]). CaMKII is a multifunctional kinase involved in
the regulation of many cell processes and its action is
dependent on intracellular Ca
2+ changes (for review see
[25]). Although we did not systematically observe spon-
taneous Ca
2+ transients in cultured trigeminal neurons,
our data suggest that in KI neurons ongoing Ca
2+ sig-
nalling was facilitated because ω-agatoxin blocked the
enhanced CaMKII activity.
We examined several intracellular targets which could
be modulated by the increased CaMKII activity. Regula-
tion of protein phosphorylation state is a common way
to modify the function of pain receptors [36]. We
observed that, under unchallenged conditions, the basal
phosphorylation state of threonine and tyrosine in P2X3
receptors of KI neurons was unchanged compared with
WT neurons. Likewise, there was no change in basal
CREB phosphorylation. However, we did observe
decreased serine phosphorylation of P2X3 receptors as
the molecular phenotype of CaV2.1-immunoreactive
neurons in KI ganglia and in culture. This phenotype
was strongly dependent on CaV2.1 channel activity and
CaMKII function, because in KI neurons, both ω-aga-
toxin and CaMKII inhibitor KN-93 restored the level of
serine phosphorylation to that of WT, and returned
P2X3 receptor responses to basal levels. Future experi-
ments are necessary to identify the mechanisms regulat-
ing the basal serine phosphorylation of P2X3 receptors
of WT cells.
Molecular mechanisms controlling P2X3 receptor
potentiation of KI neurons
The inverse correlation between P2X3 serine phosphory-
lation and P2X3 activity (i.e., reduced serine phosphory-
lation associated with enhanced P2X3 receptor function)
suggests that P2X3 serine dephosphorylation could be
an important molecular contributor to receptor opera-
tion, particularly in view of the fact that Cdk5 (a kinase
associated with negative P2X3 receptor regulating func-
tion [26]) was less associated with P2X3 receptors in
neuronal membranes of KI neurons.
We posited that, in WT neurons (either in situ or in
culture), serine phosphorylation likely depended on the
balance between kinases and phosphatases, in which
kinases were perhaps predominant and exerting a tight
regulatory role because of the consistently high basal
level of serine phosphorylation we observed. On the
Table 1 Lack of change in desensitization onset of P2X3
receptors by the calcineurin inhibitor FK-506
Phenotype Current τfast n
WT 81 ± 6 ms 14
WT + FK-506 (5 μM) 71 ± 7 ms 17
KI 91 ± 8 ms 18
KI + FK-506 (5 μM) 100 ± 9 ms 16
Data refers to the first time constant of current decay evoked by a,b-meATP
(10 μM) taken as index of desensitization.
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(as shown by decreased serine phosphorylation) and
could be restored after treatment with calcineurin inhi-
bitors like FK-506 [37-39] or the calcineurin peptide
autoinhibitor [40]. This observation indicated that the
molecular phenotype likely involved phosphatase overac-
tivity because, when the latter was pharmacologically
blocked, endogenous kinase activity readily restored ser-
ine phosphorylation. Since FK-506 is also known to
inhibit ryanodine receptors to favour intracellular Ca
2+
leakage [39], it was useful to confirm similar observa-
tions with the calcineurin peptide autoinhibitor.
The precise molecular link between Cdk5 and calci-
neurin activity in terms of P2X3 receptor function of tri-
geminal neurons remains to be clarified. Upstream of
this interaction, it is, however, interesting that Cdk5 is
reported to downregulate P/Q-type channels [41] since
in our KI model we found evidence for gain of function
of such channels together with low Cdk5 membrane
expression. Furthermore, Cdk5 activity is also negatively
associated with activation of neuronal CaMKII [42], in
analogy with the data reported in the present study. As
far as the relationship between Cdk5 and calcineurin is
concerned, these proteins appear to possess opposite
actions on a number of intracellular neuronal proteins
involved in neurotransmitter release [43,44]. Their con-
trasting actions are in keeping with the effects observed
by us and outline even a potential process to control the
release of excitatory neurotransmitter by sensory neu-
rons, a phenomenon which might enhance trigeminal
pain sensitization.
The phosphorylation state of P2X3 receptors is important
to control ATP-mediated responses of nociceptive
neurons
Potentiation of P2X3 receptor responses of WT trigem-
inal neurons observed after application of calcineurin
blockers was not accompanied by a change in receptor
serine phosphorylation, that remained at its constitutive
level. However, calcineurin inhibition enhanced P2X3
receptor threonine phosphorylation, a process that was
previously associated with PKC-dependent potentiation
of P2X3 receptor function especially after stimulation
with NGF [9].
Conversely, for KI neurons, calcineurin inhibition was
sufficient to reverse the depression of serine phosphory-
lation to a level associated with impaired receptor func-
tion despite enhanced threonine phosphorylation. Thus,
our data are consistent with the notion that the phos-
phorylation state of serine residues is dominant to regu-
late P2X3 receptor activity.
It is well established that increased concentrations of
intracellular Ca
2+ activate the protein phosphatase calci-
neurin [45,46] that is enriched in neuronal cells. We
posit that the gain-of-function of mutated CaV2.1 chan-
nels in CaV2.1-immunoreactive neurons was accompa-
nied by significant fluctuations in intracellular Ca
2+
sufficient to trigger a multisystem signaling mechanism
that probably involved CaMKII and calcineurin. In addi-
tion, enhanced influx of Ca
2+ via mutated CaV2.1 chan-
nels might modulate the activity of various transcription
factors [47] and might control neuronal gene expression
via calcineurin in distinct ways [48], conferring a new
molecular phenotype with distinctive neuronal
signalling.
Even though the structure of the P2X4 receptor in its
closed state has been recently reported [49], the numer-
ous serine residues in the N- and C-terminal domains
of the P2X3 receptor make it difficult to predict those
responsible for binding and catalytic activity of kinases
and phosphatases. Future studies will be necessary to
clarify this complex scenario in which multiple pathways
control the phosphorylation state of P2X3 receptors with
important and differential outcomes in terms of function
and thus, presumably, in terms of pain sensing
efficiency.
Conclusions
Could P2X3 upregulation be an important component of
migraine headache and to what extent do R192Q KI
mice help our understanding of the disease process?
The KI mouse model, carrying a human FHM-1 muta-
tion, through abnormal activation of CaV2.1 channels
and a CaMKII-dependent pathway, exhibited potentia-
tion of P2X3 receptor function in trigeminal neurons,
thus suggesting the role of P2X3 receptors in trigeminal
pain that requires future investigation especially because
of the role of such receptors in sporadic migraine
[13-16]. Because these purinergic nociceptors activate
one major pain transducing mechanism of the trigemi-
novascular system [50], it is attractive to think that
strong P2X3 receptor activation may facilitate ATP-
dependent migraine headache [13,14]. Furthermore, the
disabling headache attacks triggered by FK-506 treat-
ment for immunosuppression in humans [51] might
comprise a component due to intracellular Ca
2+ dysre-
gulation and potential enhancement of P2X3 receptor
function. Future studies are necessary to clarify the
mechanisms responsible for transforming acute trigem-
inal pain into the long-lasting chronic headache typical
of migraine attacks.
Methods
Genetic model
CaV2.1 a1 R192Q mutant KI and wild type (WT) litter-
mates were used for in vitro experiments. Genotyping
was performed by PCR using primers 5′-TGTCGGGAC
GGAGTTTGAC-3′ and 5′-AGACTCACGCACTTGGG
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with AlwNI (New England Biolabs, Ipswich, MA, USA)
as previously described [5]. Animals were maintained in
accordance with the Italian Animal Welfare Act and
their use was approved by the Local Authority Veterin-
ary Service.
Culture of mouse trigeminal ganglia
Trigeminal ganglion neurons were obtained from R192Q
KI and WT mice (P12-P14) and cultured as described
before [22]. Cells were used 24 h after plating. To sup-
port the comparison between KI and WT neurons, we
ran initial feasibility studies to find out any obvious
morphological or immunocytochemical differences
between trigeminal neuronal cultures of R192Q KI and
WT mice. Fig. 7A, B shows similar in vitro survival of
neuronal subpopulations (n =4 ,p > 0.05), whose largest
fraction had somatic neuronal diameter of approxi-
mately 15 μm with analogous distribution between gen-
otypes for both ganglia and cultured ganglion neurons
(Fig. 7B) in analogy with our previous observations [22].
W ea l s oc o n f i r m e dt h a tC a V2.1 a1 expression as
assessed by immunocytochemistry of intact trigeminal
ganglia showed unchanged numbers of immunopositive
cells in samples of both genotypes (Fig. 7C). Further-
more, CaV2.1 a1 western blotting confirmed this finding
and revealed similar expression levels in total membrane
fractions from trigeminal neurons from intact ganglia or
cultured ganglion neurons (CaV2.1 a1p r o t e i ns i z e :1 8 0
kDa, n =3 ,p >0 . 0 5 ;F i g .7 D ) .T h eu n c h a n g e dC a V2.1
expression levels are in line with previous observations
in the brains of R192Q KI mice [5].
The following compounds were added to the culture
medium when appropriate: ω-agatoxin (200 nM), calci-
neurin inhibitor FK-506 (5 μM), or the calcium calmo-
dulin dependent kinase II (CaMKII) inhibitor KN-93 (5
μM). These compounds were pre-applied for 60-90 min
or overnight as indicated. All compounds were obtained
from Sigma (Milan, Italy).
Immunofluorescence microscopy
For immunofluorescence microscopy, the following anti-
bodies were used: anti-P2X3, anti-P2X2, anti-TRPV1 and
anti-CaV2.1 a1 (1:200; all from Alomone Labs, Jerusa-
lem, Israel); anti-P2X3 ( 1 : 3 0 0 ;N e u r o m i c s ,E d i n a ,M N ,
USA), anti-b-tubulin III (1:1000; Sigma), anti-phos-
phorylated Thr286 CaMKII (1:500; Promega, Madison,
WI, USA), anti-phosphorylated Ser133 CREB (1:300;
Upstate Millipore, NY, USA). Antibodies were incubated
for 2 h in phosphate saline buffer plus 5% bovine serum
albumin and 0.1% Tween20. Secondary antibodies anti-
rabbit, anti-mouse or anti-guinea pig conjugated with
AlexaFluor488 or AlexaFluor594 were from Invitrogen
(1:500; S. Giuliano Milanese, Italy). Staining with
secondary antibodies only were performed as control
experiments and did not give a signal. Stained sections
were analysed with a Zeiss microscope and MetaMorph
software (Molecular Devices, Downingtown, PA, USA).
On average, 200 cells were analyzed in each test; data
are the mean of at least 3 independent experiments.
Protein lysates, immunoprecipitation and immunoblotting
For western blotting and immunoprecipitation experi-
ments, proteins from ganglia or cultures were extracted
in TNE buffer (10 mM Tris-HCl at pH 7.5, 150 mM
N a C l ,2m ME D T A ,1 0 0m MN a F ,2 %n - o c t y lb-D-glu-
copyranoside and 1% NP40) plus protease inhibitors
(Sigma). Membrane extracts were performed as
described [23]. The following antibodies were used: anti-
P2X3 (1:300; Alomone Labs), anti-P2X3 (H-60, 1:500;
Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA);
anti-cyclin dependent kinase 5 (Cdk5; 1: 400; Santa
Cruz), anti-p35 (1:200, Santa Cruz), anti-CaV2.1 a1
(1:200; Alomone Labs), anti-phosphorylated tyrosine
HRP-conjugated clone Y20 (1:3,000; Invitrogen), anti-
phospho-serine (1:600; Millipore), anti-phosphorylated
threonine (1:600; Cell Signaling Danvers, MA, USA),
anti-b-tubulin III (1:2,000; Sigma), anti-actin (1:3,000:
Sigma). To avoid complications in the analysis because
of the presence of immunoglobulin heavy chains, a
mouse anti-rabbit IgG-HRP conjugated (Jackson Immu-
noResearch, Suffolk, UK) was used as secondary anti-
body. Western blot signals were detected with the
enhanced chemiluminescence light system (GE Health-
care, Milano, Italy). For quantification, band density was
measured using CorelDraw Photopaint software and
ImageJ software. Membrane protein biotinylation and
streptavidin pulldown experiments were performed, as
described previously [9].
Real time RT-PCR
Total mRNA extraction from trigeminal cultures or
ganglia and reverse transcription reactions was per-
formed as described previously [9]. Data were normal-
ized with respect to b-tubulin III housekeeping mRNA
contents using primers previously reported [9].
Patch-clamp recording
After 1 day in culture, trigeminal neurons were super-
fused continuously (2 mL/min) with physiological solu-
tion containing (in mM): 152 NaCl, 5 KCl, 1 MgCl2,2
CaCl2, 10 glucose, and 10 HEPES (pH adjusted to 7.4
with NaOH). Cells were patch-clamped in the whole-
cell configuration using pipettes with a resistance of 3-4
MΩ when filled with the following solution (in mM):
140 KCl, 0.5 CaCl2,2M g C l 2,2M g 2ATP3,2G T P ,1 0
HEPES, and 10 EGTA (pH adjusted to 7.2 with KOH).
Cells were held at -60 mV. Currents were filtered at 1
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face and pClamp 8.2 software (Molecular Devices, Sun-
nyvale, CA, USA). To obtain stable and reproducible
P2X3 receptor currents, its synthetic agonist a,b-methy-
lene-adenosine-5′-triphosphate (a,b-meATP) was
applied using a fast superfusion system (Rapid Solution
Changer RSC-200; BioLogic Science Instruments, Claix,
France). The time for solution exchange was approxi-
mately 30 ms. Responses were measured as peak ampli-
tude, while the response riset i m ew a se x p r e s s e da si t s
Figure 7 Survival of WT and KI trigeminal neurons in culture and their expression of Cav2.1 protein. A, Survival is calculated as number
of b-tubulin III positive cells per unit area after 1-4 days in culture. Data are normalized with respect to those at 1 day. n =4 ,p > 0.05. B,
Somatic size distribution of trigeminal neurons (b-tubulin III immunoreactive) in culture from WT and KI mice. n =4 .C, Immunocytochemical
expression of CaV2.1 channels in intact trigeminal ganglia of WT and KI mice. Histograms represent% of CaV2.1 immunoreactive neurons over b-
tubulinIII immunoreactive neurons in WT or KI ganglia. n =3 ,p > 0.05. D, Example of western blot of protein extracts from WT and KI trigeminal
ganglia or culture, probed with anti-CaV2.1 antibody. Equal loading was ensured by membrane probing with b-tubulinIII antibodies. n =3 ,p >
0.05. Histograms (right) show no significant difference between these conditions.
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not decay to baseline prior the end of agonist applica-
tion, we considered the residual current as indicative of
heteromeric P2X2/3 receptors [21] and measured it to
quantify its size and occurrence. To express agonist
potency as EC50 values (concentration producing 50% of
the maximum response), dose-response curves were
constructed by applying different agonist doses to the
same cells, and fitting them with a logistic equation
(Origin 6.0; Microcal, Northampton, MA, USA). The
onset of desensitization was estimated by calculating the
first-time constant of current decay (τfast)i na c c o r d a n c e
with our previous reports [52]. Previous studies have
indicated that recovery from desensitization of P2X3
receptors is a relatively slow process which depends on
the agonist used for the test [52,53]. In the case of a,b-
meATP, the half-time recovery is typically under 1 min
a n dt h u s ,w eu s et h ea m p l i t u d eo fas e c o n dr e s p o n s e
evoked by a,b- m e A T P3 0sa f t e rt h ef i r s to n ea sas i m -
ple index to assess the extent of recovery from desensiti-
zation in accordance with former reports [9,22].
Heteromeric responses of native P2X2/3 receptors were
identified on the basis of their residual current (≥5% of
peak current) at the end of a 2-s-long agonist applica-
tion as previously reported [9]. Capsaicin was applied at
the standard test dose of 1 μM (for 2 s) to evoke repro-
ducible inward currents. Functional current responses
were recorded approximately 10 min after washout of
the culture medium. To quantify the effect of a drug on
the a,b-meATP-induced current amplitude for a drug-
treated neuron, the peak response was expressed as a
percentage of the mean peak current amplitude obtained
from control neurons from cultures prepared in parallel.
Ca
2+ imaging
Cultured trigeminal neurons were incubated for 40 min
at 20-22°C in physiological solution containing Fluo3-
AM (5 μM ;I n v i t r o g e n )f o l l o w e db yaw a s hf o r3 0m i n .
Fluorescence emission signals were acquired with a
CCD camera (Coolsnap HQ; Roper Scientific, Duluth,
GA, USA). We did not observe any difference in dye
loading between WT and KI neurons. Data were col-
lected from cells that produced a rapid response to a
pulse of high concentration of KCl (i.e., 50 mM for 1 s)
to maximize the activation of voltage-dependent Ca
2+
channels: their responsiveness indicated that they were
neurons [10]. We could not detect any difference in the
amplitude of such responses between WT and KI neu-
rons tested in parallel with sister cultures. For routine
testing of the neuronal excitability we used 20 mM K
+
to stimulate neurons without excessive depolarization
and 10 μM a,b-meATP in analogy to patch clamp pro-
tocols. The analysis was performed using Metafluor
software (Metafluor Imaging Series 6.0; Molecular
Devices). Intracellular Ca
2+ transients are expressed as
fractional amplitude increase (ΔF/F0,w h e r eF0 is the
baseline fluorescence level and ΔF is the increment over
baseline). To test the effect of ω-agatoxin (200 nM) on
Ca
2+ transients, neurons were challenged with a 2-s
pulse of a,b-meATP, capsaicin, 20 mM K
+,5 0m MK
+
before and after 30 min application of ω-agatoxin.
Pharmacological inhibitors
Pharmacological blockers were used to support our bio-
chemical and electrophysiological data suggesting a role
for certain enzymes and channels in the observed
mouse neuron phenotype. In particular, we used ω-aga-
toxin (200 nM) as a selective inhibitor of P/Q-type Ca
2+
channels [54]: this toxin has been extensively employed
to probe the influence of such channels on a variety of
in vivo pain models [55,56] including trigeminal neu-
rons [57]. To block activated CaMKII, we used KN-93
(5 μM; see also [11]), an agent widely employed to
depress experimental pain [58-60]. Conversely, we also
applied FK-506 (5 μM), a well known immunosuppres-
sant drug that acts by binding to proteins regulating the
Ca
2+-dependent phosphatase calcineurin [39]. This drug
can induce strong, persistent pain in humans [61],
including severe headache [51]. We also tested the cal-
cineurin autoinhibitory peptide F2/47 (100 μM; Tocris,
Bristol, UK) [40] applied via the intracellular solution in
patch clamp studies.
Statistics
Data are expressed as mean ± standard error of the
mean (SEM), where n indicates the number of experi-
ments in molecular biology/immunocytochemistry or
the number of investigated cells in electrophysiology
(unless stated otherwise). Statistical analysis was per-
formed using the Student’s t-test, the Mann-Whitney
rank sum test or the ANOVA test, when appropriate for
parametric or non-parametric data, respectively.
A p value of ≤ 0.05 was accepted as indicative of a
statistically significant difference.
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